Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ients with evaluable GCase data, and 5 of the 6 patients without a clear increase were either in the lowest dose cohort or the cohort dosed least frequently. As expected in this short term study, the levels of relevant hematological markers of Gaucher disease remained stable.

Amicus has amended the protocol for the 6-month Phase 2 clinical trial of Plicera patients naive to ERT to include modified doses and dose regimens. Amicus expects the results of this study to be available in 2009. In addition, in the second half of 2008, the Company expects to initiate a longer-term study in individuals switching from ERT to Plicera.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic drug candidate being developed for the treatment of Pompe disease. At the ACMG meeting in March, clinical investigators presented encouraging results from an ex vivo response study in cells from patients with Pompe disease as well as three Phase 1 clinical trials of AT2220 in healthy volunteers. The ex vivo response study was designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells from these samples where then treated with AT2220. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T > G. Data from the Phase 1 trials in a total of 72 healthy volunteers showed that AT2220 was generally safe and well tolerated at all doses.

In the second quarter of 2008, Amicus plans to initiate a Phase 2 clinical trial of AT2220 in patients with Pompe disease. The Company also plans to consider the initiation of a clinical trial of AT2220-ERT combination treatment in Pompe patients later in 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... IRVING, Texas , May 27, 2015 ­ /PRNewswire/ ... on fulfilling the promise of precision medicine, today announced ... Carolinas HealthCare System, a center of excellence site in ... (Network). Levine Cancer Institute is one ... and treats more than 11,000 new cancer patients annually. ...
(Date:5/26/2015)... May 26, 2015 WORMS, GERMANY ... & Co. (NYSE: GRA) announces that its manufacturing ... practice (GMP) certification from EXCiPACTâ„¢, an independent organization ... excipients. , All three Grace facilities ... grade excipient silica gels have now received GMP ...
(Date:5/26/2015)... HILDEN, Germany , May 26, ... QGEN ; Frankfurt Prime Standard: QIA) today ... Insight ® (QCI™) bioinformatics content and software ... report on genomic variants identified in next-generation sequencing ... bioinformatics platform are in oncology, for somatic and ...
(Date:5/26/2015)... Mass. , May 26, 2015  Alere Inc. (NYSE: ... result of its failure to timely file its Quarterly Report ... 2015 (the "Form 10-Q"), it has received a notice from ... is not in compliance with the NYSE,s continued listing requirements ... the NYSE Listed Company Manual. The reason ...
Breaking Biology Technology:Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5
... Einstein Wireless , a Wisconsin-based wireless carrier, has launched ... phone about natural disasters, terrorist attacks, and other life-threatening ... in the United States, will use Einstein's GSM network, ... of Wisconsin, and notification equipment from the Houston-based ...
... Editor's note: We've heard about the merits of electronic ... vendors, but what do insurer's make of the industry's electronic push? ... , views the benefits in much the same way and he ... , , Excerpts of the interview are as follows: ...
... guidance from the Public Company Accounting Oversight Board ... management within information systems. There are numerous studies, including ... problem area. It is worth making the investment to ... cost savings with your Sarbanes-Oxley compliance program. ...
Cached Biology Technology:Visions: Preizler offers insurer's perspective on healthcare IT 2Visions: Preizler offers insurer's perspective on healthcare IT 3Visions: Preizler offers insurer's perspective on healthcare IT 4Visions: Preizler offers insurer's perspective on healthcare IT 5Visions: Preizler offers insurer's perspective on healthcare IT 6Visions: Preizler offers insurer's perspective on healthcare IT 7Why IT change management is more important than ever 2Why IT change management is more important than ever 3Why IT change management is more important than ever 4
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... Sphagnum palustre appears to be a clone that ... discovered. The study is published in New Phytologist . ... the Hawaiian population appears to have been produced by vegetative ... a single parent. Surprisingly, the genetic diversity of the ...
... RIVERSIDE, Calif. University of California, Riverside scientists released ... (ACP) yesterday on campus to help control the spread of ... $1.1 billion citrus industry and citrus trees in home landscapes. ... been released in California. UC Riverside Executive Vice Chancellor ...
... of the return of wolves to Yellowstone National Park, a ... emerging, scientists conclude in a new report. For the ... and willow trees has diminished as elk populations in northern ... and shrubs have begun recovering along some streams, providing improved ...
Cached Biology News:UC Riverside scientists release natural enemy of Asian citrus psyllid 2UC Riverside scientists release natural enemy of Asian citrus psyllid 3UC Riverside scientists release natural enemy of Asian citrus psyllid 4An ecosystem being transformed - Yellowstone 15 years after the return of wolves 2An ecosystem being transformed - Yellowstone 15 years after the return of wolves 3
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Slide Chambers are convenient for performing pre-hybridization incubations and post-hybridization washes with tissue sections mounted on standard glass microscope slides. Each chamber holds up to 5 s...
Biology Products: